Patents Assigned to DirectContact LLC
  • Device and method for the delivery of drugs for the treatment of posterior segment disease
    Patent number: 9216106
    Abstract: Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.
    Type: Grant
    Filed: September 2, 2008
    Date of Patent: December 22, 2015
    Assignee: DIRECTCONTACT LLC
    Inventors: Clyde L. Schultz, Jerome J. Schentag
  • Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
    Patent number: 7618643
    Abstract: The present invention features hydrogel drug delivery systems and methods of producing and using such systems for the treatment of wounds. The systems are based on a hydrogel into which a low concentration of growth factor, e.g., epidermal growth factor, is passively transferred from a dilute aqueous solution. When placed in contact with a wounded tissue, the growth factor passively transfers out of the contact lens to provide accelerated healing. The systems are applicable to ocular and other wound treatments.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: November 17, 2009
    Assignee: DirectContact LLC
    Inventor: Clyde L. Schultz
  • Device and Method for the Delivery of Drugs for the Treatment of Posterior Segment Disease
    Publication number: 20080318843
    Abstract: Hydrogel lenses are infused with a drug for the treatment of posterior segment disease. The lenses are placed in contact with the subject's cornea. Drugs can be passively released from the hydrogel and can migrate around the globe of the eye to the posterior segment.
    Type: Application
    Filed: September 2, 2008
    Publication date: December 25, 2008
    Applicant: DirectContact LLC
    Inventors: Clyde L. Schultz, Jerome J. Schentag
  • Growth factor delivery systems for the healing of wounds and the prevention of inflammation and disease
    Patent number: 7169406
    Abstract: The present invention features hydrogel drug delivery systems and methods of producing and using such systems for the treatment of wounds. The systems are based on a hydrogel into which a low concentration of growth factor, e.g., epidermal growth factor, is passively transferred from a dilute aqueous solution. When placed in contact with a wounded tissue, the growth factor passively transfers out of the contact lens to provide accelerated healing. The systems are applicable to ocular and other wound treatments.
    Type: Grant
    Filed: January 10, 2003
    Date of Patent: January 30, 2007
    Assignee: DirectContact LLC
    Inventor: Clyde L. Schultz